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Abstract
Background: Evidence mapping is an emerging tool used to systematically identify, organize and summarize the
quantity and focus of scientific evidence on a broad topic, but there are currently no methodological standards.
Using the topic of low-calorie sweeteners (LCS) and selected health outcomes, we describe the process of creating
an evidence-map database and demonstrate several example descriptive analyses using this database.
Methods: The process of creating an evidence-map database is described in detail. The steps include: developing a
comprehensive literature search strategy, establishing study eligibility criteria and a systematic study selection process,
extracting data, developing outcome groups with input from expert stakeholders and tabulating data using descriptive
analyses. The database was uploaded onto SRDR™ (Systematic Review Data Repository), an open public data repository.
Results: Our final LCS evidence-map database included 225 studies, of which 208 were interventional studies and 17
were cohort studies. An example bubble plot was produced to display the evidence-map data and visualize research
gaps according to four parameters: comparison types, population baseline health status, outcome groups, and study
sample size. This plot indicated a lack of studies assessing appetite and dietary intake related outcomes using LCS with
a sugar intake comparison in people with diabetes.
Conclusion: Evidence mapping is an important tool for the contextualization of in-depth systematic reviews within
broader literature and identifies gaps in the evidence base, which can be used to inform future research. An open
evidence-map database has the potential to promote knowledge translation from nutrition science to policy.
Keywords: Evidence map, Evidence-based methodology, Low-calorie sweeteners, Artificial sweeteners, High intensity
sweeteners
Background
Evidence mapping is an emerging tool to systematically
and comprehensively identify, organize and summarize
the distribution of scientific evidence on a broad topic
[1, 2]. It can be thought of as a first step in conducting
a broad systematic review, or organizing several related
systematic reviews of published literature. However,
unlike a systematic review, evidence mapping does not
require a risk-of-bias appraisal of the included studies
or detailed extraction and synthesis of the studies’
findings [1, 3]. Instead, it descriptively summarizes the
characteristics of existing literature, typically in tabular
forms, known as evidence (gap) maps [4]. These de-
scriptive analyses can clarify where there is sufficient
evidence to inform policy development, as well as
identify research-dense areas where systematic reviews
can be pursued [1, 3–7]. Conversely, evidence maps
can also clarify areas where there is missing or inad-
equate evidence, known as research gaps [8]. These
gaps can inform researchers and policy makers where
strategic research prioritization is needed for future,
focused studies [1–6, 8–10]. Aside from these utilities,
there are other versions of evidence mapping with dif-
ferent focuses. For example, a scoping map or scoping
review emphasizes capturing the entire scope of the* Correspondence: Mei_Chun.Chung@tufts.edu1Department of Public Health and Community Medicine, Tufts University
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evidence and tends to include ongoing research [7].
The use of evidence mapping to present characteristics
of relevant studies as well as research gaps can poten-
tially provide a cost-effective methodology to facilitate
evidence-based decision-making [2, 3, 6, 11].
There are currently no methodological standards for
evidence mapping [12]. As described earlier, discrepan-
cies exist between the terminology and methods used
within evidence mapping. Various terms, including evi-
dence map, scoping review and systematic map, are
widely used within evidence mapping, yet there are some
differences between them [7]. Nonetheless, the following
key steps are generally followed in all types of evidence
mapping: 1) Identifying a broad research area of interest
and defining the key variables and framework for
descriptive analysis; 2) Developing a thorough, clear and
reproducible literature search strategy; 3) Establishing
the a priori inclusion and exclusion criteria; and 4) Sys-
tematically extracting, coding, sorting and reporting the
findings in a tabular evidence map. It is preferable to
consult with key stakeholders to guide these steps and to
validate the findings [2, 4, 13].
In this paper, we describe the process and methodology
of creating an evidence map database, using the topic of
low-calorie sweeteners (LCS) and selected health out-
comes of interest as a worked example. We also demon-
strate several example descriptive analyses by using data
in the LCS evidence map to help identify potential gaps
and future research directions.
Methods
Seven steps were used to construct a LCS evidence-map
database: 1) Identify the Scope of the Evidence Map; 2)
Define the Roles and Responsibilities of Different Parties:
Stakeholder Panel and Research Team; 3) Develop a
Comprehensive Search Strategy; 4) Establish Study Eligi-
bility Criteria and a Systematic Study Selection Process;
5) Carry Out Abstract Screening and Selection; 6) Carry
Out Data Extraction; and 7) Classify Outcome Categor-
ies. Details are described as follows.
Identify the scope of the evidence map
The initial scope of work was developed by the sponsor
of this project in a request-for- proposals. The following
five areas of research regarding the potential health
effects of LCS were all considered and included: 1)
energy sensing by the brain; 2) gut hormones that may
influence energy homeostasis; 3) satiety and preference
for taste; 4) eating behavior; and 5) body weight and
composition. It is important to note that, aside from
their initial feedback on our funded research proposal,
the sponsor was not involved in the later refinement of
the work scope or the process of creating the evidence-
map database other than providing a list of selective
citations for cross-referencing purposes.
Establish roles and responsibilities of different parties:
stakeholder panel and research team
A diverse stakeholder panel was recruited across eight
areas of expertise: one physician, two dietitians, three
policymakers, a research funder, academic researchers
from five different fields, two representatives from the
food industry, one journalist and one lay person. The
panel served as a steering committee to guide the research
team through the process of building the LCS evidence-
map database. Specifically, the stakeholder panel helped
refine the search strategy, finalize study eligibility criteria
and define outcome groups for evidence map analysis and
charting. Data screening, collection and analyses were per-
formed by the research team. The research team included
a methodologist with expertise in conducting and leading
systematic reviews and meta-analyses, two team members
with graduate-level epidemiology training and a research
coordinator.
Develop a comprehensive search strategy
The research team collected key search terms from pre-
vious reviews and systematic reviews on relevant topics
to formulate the initial search strategy [14–16]. The
search strategy was developed using both keywords and
the National Library of Medicine’s Medical Subject
Headings (MeSH). Duplicated citations were removed in
MEDLINE® and Endnote®. The search was also cross-
referenced with published systematic reviews to make
sure all of the relevant articles were included. Publica-
tion citations were exported from electronic search
interfaces and stored in a Microsoft Excel spreadsheet.
The relevance of the publications was determined based
on pre-determined inclusion and exclusion criteria using
a two-step screening process: 1) title and abstract
screening and 2) full-text article screening, which is
described later in detail. The initial literature search and
abstract screening were conducted by the research team.
After the screening was completed, the panel provided
input and suggested additional key terms to refine the
search strategy. The research team then carried out this
supplemental search, retrieved the citations and
screened this additional round of abstracts. Included
abstracts from both screening rounds were then merged
into the same pool for full-text screening. The final
search strategy of the LCS evidence map is described in
Additional file 1: Table S1.
Establish study eligibility criteria and a systematic study
selection process
The research team used an iterative process to establish
study eligibility criteria, with input from the stakeholder
Wang et al. BMC Medical Research Methodology  (2016) 16:1 Page 2 of 11
panel collected via webinars and online surveys. After 2
iterations, the stakeholders and research team decided
that for studies to be included, they needed to be: 1) ran-
domized or non-randomized, controlled, clinical trials or
prospective cohort study designs, which are considered
the strongest study designs for causal inferences; 2) in-
vestigating orally administered, FDA-approved LCS or
LCS that are generally recognized as safe (GRAS); 3)
reporting at least one health outcome within the five cat-
egories in our scope of work; 4) an English publication;
and 5) human subjects research. Articles with study pop-
ulations including adults, children, adolescents, pregnant
women and infants greater than 6 months old were
included, whereas studies in cancer patients and cancer
outcomes were excluded because the project scope
includes only FDA-approved LCS that have passed FDA’s
toxicological safety assessment as food additives, which in-
cludes assessment for cancer risks. A search of systematic
reviews and meta-analyses was also conducted in addition
to the main search for reference-mining purposes.
Carry out abstract screening and study selection
The titles, abstracts and keywords of all identified articles
were screened using Abstrackr™, an open source, web-
based, citation screening tool [17]. The research team
screened study abstracts using inclusion and exclusion cri-
teria and assigned a decision (“yes”, “maybe” or “no”) to
each abstract. Two rounds of pilot tests for a total of 1000
abstracts were screened by all reviewers to calibrate
screening accuracy between reviewers. Discrepancies of
the pilot abstracts were discussed among reviewers until
complete agreement was reached and team members fully
understood the selection criteria. The remainder of the
abstracts (n = 11,830) were single-screened due to the
large number of abstracts and budgetary constraints. Ab-
stracts with a “yes” or “maybe” label were both included in
step 1 of the evidence map and the full-text articles of
these abstracts were retrieved for full-text screening. Cita-
tions with a “no” label were saved for record. Because of
the single screening process, it is possible that a few
abstracts were mistakenly rejected during this screening
phase. In an effort to ensure all key studies were included,
all included citations were cross-referenced with the refer-
ence list of relevant systematic reviews and meta-analyses.
In step 2 (full-text screening), we followed the predefined
study eligibility criteria (Table 1) and recorded the reasons
for rejection of each rejected article. About 5 % (n = 571)
of the original citations were screened in for full-text re-
view. Each full-text article was screened by one reviewer,
and the screening decision of the first reviewer was then
confirmed or disputed by a second reviewer. Discrepan-
cies were resolved through consensus among all research
team members.
Carry out data extraction
The research team extracted data on a customized
extraction form shared via Google Drive to facilitate collab-
oration among research team members and allow for sim-
ultaneous data entry. The minimal data to collect for an
evidence-map database are the information related to the
PI(E)COS (Population, Intervention/Exposure, Comparator,
Outcome and Study design). The extraction form for the
LCS evidence-map database was designed to collect the fol-
lowing data from each study: study design characteristics
(study design, study duration), study population character-
istics (baseline health status, age, sample size, anthropomet-
rics), study interventions/exposures and comparisons (type
of LCS, comparison or control group, number of people
analyzed, form of administration), outcome information
(all outcomes or endpoints of interest), the aim or hypoth-
esis of the study and funding source of the study. The ex-
traction form was designed and finalized by the research
team lead, who has expertise in evidence-based research
and methods. The evidence-map database was uploaded
onto SRDR™, an open public data repository, and a data-
base codebook is included in the supplemental material
(Additional file 2) [18].
Classifications of outcome categories
One of the most important features of an evidence map
is the cataloging of the large number and variety of out-
comes reported in the published literature. This step
typically occurs after data extraction since the scope of
an evidence-map database is large. Thus, it is often diffi-
cult to pre-define all outcome categories of interest. The
research team worked with the stakeholder panel to
classify outcomes into clinically and biologically mean-
ingful outcome categories that could be used in
evidence-map analyses. The research team recorded out-
comes reported in each publication and took the first at-
tempt in identifying clinically and biologically relevant
groups. Standardized coding was then developed for
each outcome category. Feedback was sought from the
stakeholder panel, and the outcome categories and cod-
ing were modified based on the final consensus of the
stakeholder panel. Table 2 shows the final list of out-
comes for each outcome category that are reported in
Table 1 Study eligibility criteria





control trials or single)
• Adults; Pregnant women
and infants (>6 months)
• Prospective cohort studies
• FDA-approved sweeteners
• Animal studies
• In vitro cell studies
• Case–control, cross-sectional
studies; Reviews, interviews,
bibliographies, letters, or guidelines
• Systematic reviews and meta-analysis
• Cancer patients
• Non-oral intake
Wang et al. BMC Medical Research Methodology  (2016) 16:1 Page 3 of 11
the studies included in the LCS evidence-map database.
Specifically, outcomes related to appetite or satiety rat-
ings such as hunger score and desire to eat were often
rated by a visual analog scale (VAS) and were classified
under the ‘Appetite’ category. Outcomes focused on
neurological measurements and sensing signals by the
brain were classified under the ‘Energy Sensing’ category.
Body weight, body composition and changes in weight-
related outcomes were classified under the ‘Body Weight
or Composition’ category. The ‘Dietary Intake’ category
included outcomes such as energy intake, dietary intake,
food intake and carbohydrate intake, and finally the ‘Gly-
cemic’ category included glucose, insulin and gastric
hormones. Our stakeholder panel did not identify add-
itional outcomes that were not reported in the literature.
Both outcome categories and full outcome lists were in-
cluded in the evidence-map database, which can be used
in future analyses with current or new outcome category
coding.
Results
The following sections demonstrate several example
descriptive analyses by using data in the LCS evidence
map to help identify potential gaps and future research
directions. Using data stored in the evidence-map data-
base, descriptive analyses can be performed to describe
study design and population characteristics. All analyses
and charting were performed using Stata 2013 (Stata
Statistical Software: Release 13. College Station, TX:
StataCorp LP) and Microsoft Excel.
Summarize study and sample characteristics
The original search on MEDLINE® from inception to
June 2014 yielded 12,830 citations. The supplemental
search including terms recommended by the stakeholder
panel yielded 4440 additional citations. In total, 17,270
relevant citations were screened. After title and abstract
screening, 571 articles were included in full-text screen-
ing. Our final LCS evidence-map database included 225
studies, of which 208 were interventional studies and 17
were cohort studies. The literature search and study
selection process are summarized in Fig. 1.
Among the 208 included intervention studies, 183
(88 %) were done in adults, 51 % of the study popula-
tions were male and 140 (68 %) of the studies included
only healthy subjects with no known diseases. The mean
sample size was 48 subjects (range: 2–732 subjects) and
the mean BMI across studies was 25.6 kg/m2 (range:
16.1–42.3 kg/m2). The mean age was 31 years old
(range: 8–73 years old). Fifty-seven percent of the trials
were randomized cross-over trials and 28 % were ran-
domized parallel controlled trials. Eleven percent of the
trials were non-randomized crossover or parallel trials.
More than half of the trials (60.1 %) were acute studies,
defined as less than 1 day in study duration. Among the
17 cohort studies, the BMI (mean of the means) was
23.6 kg/m2 (range: 16.2–27.4 kg/m2). There were 6 stud-
ies conducted on children and 11 on adults. The mean
age was 32 years old (range: 2–84 years old) with an
average sample size of 15,430 subjects (164–31,940 sub-
jects) (Table 3). Of the 17 cohort studies included, all
were conducted in the United States and reported body
weight and dietary intake outcomes. We did not identify
any cohort studies that investigated appetite, glycemic or
brain energy sensing outcomes. There were nine studies
that used a food frequency questionnaire, five studies
that used 24-h recalls or food diaries and three studies
that used a specific beverage questionnaire. As for LCS
intervention/exposure, eight studies reported it as LCS
beverage intake, two as saccharin intake, and seven as
unspecified, artificially-sweetened, carbonated drink in-
take, diet drink or diet soda intake.
Summarize by types of outcomes
Studies in the evidence-map database can be summarized
using the outcome categories described earlier. Among
the 208 intervention studies identified, 84 studies reported
appetite-related outcomes, 75 studies reported energy
sensing-related outcomes, 35 studies reported body weight
or body composition outcomes, 62 studies reported diet-
ary intake-related outcomes and 76 studies reported gly-
cemic outcomes. All 17 cohort studies reported body
weight or body composition outcomes. Table 4 displays
the type of LCS intervention or exposure, baseline health
Table 2 Outcomes of interest by outcome groups in the LCS evidence-map database
Outcome groups Outcomes of interest
Appetite Appetite ratings using a visual analog scale (VAS), hunger, desire to eat, fullness, prospective consumption, thirst,
motivational and behavioral factors reported through questionnaire
Energy sensing by brain Neurological measurements (fMRI, EEG), sensory rating (sweetness, intensity, pleasantness, sensory specific
satiation), taste, perception and preference, taste reaction time
Body weight or body composition Body weight, body composition, BMI, waist circumferences, weight or BMI changes
Dietary intake Energy intake, dietary intake, food intake, carbohydrate intake, sugar intake, salt intake, water intake
Glycemic Glucose, Hemoglobin A1c (HbA1c), insulin concentration, insulin sensitivity, hypoglycemia, glucagon,
glucose-dependent insulinotropic peptide (GIP), glucagon-like peptide-1 (GLP-1), peptide tyrosine tyrosine (PYY),
cholecystokinin (CCK), enterostatin, ghrelin, leptin, somatostatin, oxyntomodulin
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status of the study population, age of the study popula-
tion, sample size and trial country by outcome category
in the 208 intervention and 17 cohort studies. Briefly,
the majority of the studies were conducted in the
United States and in Europe using LCS in a beverage
intervention among healthy, young adults.
Summarize publication patterns
A cumulative frequency chart of the number of publica-
tions by outcome categories was produced to show the
cumulative publication growth over time. As shown in
Fig. 2, there is an increasing trend in the number of pub-
lications reporting energy sensing and appetite-related
outcomes from 1980 to 1995, and again from 2008 to
2014. The increasing interest of glycemic outcomes slo-
wed down at 1991 and again spiked up at 2003. Up until
2014, there were larger cumulative numbers of publica-
tions reporting energy sensing, appetite and glycemic
outcomes compared to energy intake and body weight
or body composition outcomes (Fig. 2).
Using a bubble plot to identify research gaps
A scatter plot is often used to identify relationships or pat-
terns. A bubble plot is a variation of a weighted scatter
plot, which was used here for the purpose of identifying
research gaps. A bubble plot can graphically present mul-
tiple categorical data on study characteristics in a single,
two-dimension chart by displaying the evidence-map data
according to specific, special locations defined by the x-
axis and y-axis, as well as according to the color, shape or
size of bubbles. In the construction of the bubble plot
using data in the LCS evidence-map database, the unit of
the analyses was the individual study. One study could be
included multiple times in an analysis because each study
could report multiple outcomes of interest.
In the example bubble plots (Figs. 3 and 4), studies in
the LCS evidence-map database are plotted into two-
dimensional grids according to outcome categories and
study characteristics such as intervention duration, inter-
vention type, or population health status. Each data
point is randomly scattered in each grid to maximize
Fig. 1 Literature search and selection process
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visualization of each bubble (so that not all bubbles
overlaid with each other). The sample size of each study
is shown as the weight of the bubble. Therefore, a larger
bubble represents a larger study sample size. In the first
example, bubble plot data points are grouped and plot-
ted by study duration and outcome categories. This ex-
ample bubble plot shows that the majority of LCS
studies are acute (<1 day in duration) and short-term (1
to 30 days in duration) studies for all outcome categor-
ies, except for body weight or body composition out-
comes. A majority of the studies report body weight or
body composition outcomes with duration greater than
1 month (Fig. 3).
In the second example, bubble plot data points are
grouped and plotted according to population health sta-
tus and outcome categories. The plot is further stratified
by two types of intervention and comparison designs: 1)
LCS versus sugars (or vice versa) or 2) LCS versus other
non-sugar comparisons (or vice versa) (Fig. 4). This ex-
ample bubble plot shows that there are more studies in
generally healthy populations compared to other popula-
tion types across all outcome categories. The empty
grids on the plot show that there is a lack of studies
assessing appetite and dietary intake outcomes using a
LCS intervention with a sugar intake comparison in
people with diabetes. Most studies in people with
Table 4 Study features of published LCS intervention studies (n = 208) and cohort studies (n = 17) by health outcome groups
Outcome group
(number of studies)














Appetite (84) Beverage (54),
Food or meal (22),
Supplement or
oral rinse (8)
RCT-c (48), RCT-p (22),
nRCT-c (11), nRCT-p (1),




24.1 52 United States (41),





Food or meal (10),
Supplement or
oral rinse (7)
RCT-c (48), RCT-p (10),






26.1 47 United States (43),






Food or meal (13),
Supplement or oral (8)
RCT-c (7), RCT-p (25),





35.6 92 United States (19),
Europe (10), Asia (3),




Beverage (17) Cohort (17) Healthy (17) 32.0 15,430 United States (1),
Europe (1)
Dietary Intake (62) Beverage (39),
Food or meal (19),
Supplement or
oral rinse (4)
RCT-c (33), RCT-p (20),






27.2 39 United States (29),
Europe (22), Canada (9),
Australia (1), NR (1)
Glycemic (76) Beverage (42),




RCT-c (51), RCT-p (21),





37.6 31 United States (28),
Europe (27), Asia (8),
Australia (7), Canada (3),
Africa (1), Not reported (2)
NR Not reported, RCT-c Randomized controlled trial-crossover design, RCT-p Randomized controlled trial-parallel design, nRCT-c Non-randomized controlled
trial-crossover design, nRCT-p Non-randomized controlled trial-parallel design
Table 3 Summary of study design and population
characteristics of the intervention in the evidence map
Intervention studies (n = 208)
Study design N (%) Population N (%)
RCT-c 119 (57.7) Adults 183 (88 %)
RCT-p 58 (27.9) Children 14 (7 %)
nRCT-c 21 (10.1) Adolescents 2 (1 %)
nRCT-p 2 (1.0) Mixed 6 (3 %)
Single arm 6 (2.9) Unsure 2 (1 %)
Unclear 1 (0.5) Baseline health N (%)
Length N (%) Healthy 140 (68 %)
< 1 day 124 (60.1) Overweight/
Obese
19 (9 %)
2 day-1 month 37 (17.8) Diabetic 17 (8 %)
1–6 months 30 (14.4) Mixed 14 (7 %)
6 months–1 year 1 (0.5) Other 17 (8 %)
> 1 year 7 (3.3) Age, Mean (Range) 31 (8–73)
Not reported 8 (3.8) BMI, Mean (Range) 25.6 (16.1–42.3)
Sample size,
Mean (range)
48 (2–732) % Male 51 % (0–100 %)
Data missing for age: n = 2, % male, n = 29, and BMI n = 87. RCT-c Randomized
controlled trial-crossover design, RCT-p Randomized controlled trial-parallel
design, nRCT-c Non-randomized controlled trial-crossover design, nRCT-p
Non-randomized controlled trial-parallel design. Mixed or other: A mixture of
healthy and overweight, healthy and diabetic, or overweight and diabetic
population, and other population: patient or people with disease at baseline
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Fig. 3 Example bubble plot of LCS studies by intervention duration and outcome categories. Legends: Each bubble represents one single study.
Bubble size corresponds to study sample size
Fig. 2 Cumulative growth of published LCS studies (n = 208)
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diabetes reported body weight or body composition and
glycemic outcomes. Among trials comparing LCS to sugar,
there are a limited number of studies that investigated
brain energy sensing outcomes in people who are over-
weight or who have diabetes.
It is important to note that the research gaps identi-
fied by the bubble plots do not necessarily equate to re-
search needs. Besides the quantity and quality of the
existing studies, the importance, desirability, feasibility,
and potential impact of research gaps need to be con-
sidered to determine the research needs. For example,
while a research gap exists regarding LCS vs. sugar in-
takes in diabetic populations, experts in this area would
need to determine if there is a further need, given that
individuals with diabetes need to limit their added
sugars intake. The LCS evidence map database and ana-
lyses presented here were an integral component of a
Future Research Needs (FRN) assessment project. The
stakeholder panel in this project was assembled to pro-
vide input for the FRN project according to a frame-
work for stakeholder engagement in patient-centered
outcome research to identify research needs in the
broad field of LCS and potential health-related out-
comes [22].
Discussion
This paper reviewed the components of an evidence
map and described the steps in the process of construct-
ing a LCS evidence map as a worked example. The
methodology presented to create the evidence map is
replicable and helps readers understand the steps re-
quired to build a comprehensive database. These steps
can be applied to create an evidence-map database for
any research topic of interest. We have applied the same
methodology to create two other evidence-map data-
bases–one on the health effects of added sugars and
another on fiber [19, 20]. The potential target users of
evidence-map databases are researchers, research fun-
ders and policy makers, who can use the databases to
identify research gaps and to evaluate the quantity of
evidence accumulated for a specific research questions.
Although evidence mapping is not a new method, it has
only recently been applied in the fields of nutritional epi-
demiology and evidence-based nutrition. Because of the
complexity of nutrition and chronic disease relation-
ships, the decision makers often need to evaluate large
arrays of interventions or exposures, comparisons and
outcomes in comprehensive evidence reviews and synthe-
ses. However, the resources (time and money) needed are
Fig. 4 Example bubble plot of LCS studies by intervention type and health status. Legends: LCS vs. Sugars: An intervention comparison between
LCS and sugars or sugars and LCS; LCS vs. Others: An intervention comparison between LCS and non-sugar arm or a single arm study. Other or
mixed: A mixture of healthy and overweight, healthy and diabetic, or overweight and diabetic population, and other population: patient or
people with disease at baseline. Each bubble represents one single study. Bubble size corresponds to study sample size
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increasing with the steadily upward trends in the number
of scientific publications every year. Thus, establishing
multiple, open evidence-map databases for nutrition re-
search sets the much needed foundations for evidence-
based nutrition guidelines or policy development. Open
evidence-map databases increase transparency and can fa-
cilitate future updates. Evidence-map databases can be
used to query what has been done based on a specific re-
search question of interest in a broad area. Study charac-
teristics can be summarized using the data in the evidence-
map database to inform future study designs or to identify
areas in need of more research with input from stake-
holders. Conversely, evidence mapping can also help iden-
tify areas rich in studies, for which systematic reviews and
meta-analyses can be conducted. Such systematic reviews
and meta-analyses may be used in evaluating the science
for public nutrition policy recommendations (e.g., Dietary
Guidelines for Americans). By using a systematically
collected and organized knowledge base, Research funders,
researchers and practitioners can easily query and analyze
the evidence-map databases to acquire information neces-
sary for decision-making, such as directions for future
research and the basis for evidence synthesis in a fraction
of the time needed to conduct comprehensive literature re-
views. Subsequently the process of knowledge translation
from scientific findings into health practice or policy rec-
ommendations can be substantially shortened (Fig. 5).
Our LCS evidence-map database has several limita-
tions. Due to limited resources, only the Medline® data-
base was searched; thus the evidence-map database
cannot be the sole source of data when used as the basis
for a systematic review. We encourage future evidence
map projects to include databases such as EMBASE,
Cochrane, Scopus and other databases deemed appropri-
ate to the research question. With more databases
searched, it is expected that the number of abstracts and
full-text articles to be screened will rise substantially.
Hence, it is important to evaluate the project feasibility
by looking at the number of search hits at the beginning
of the project. Regardless of the comprehensive search
strategy, it is likely we missed studies that did not
include key LCS or outcome terms in the abstract or
keywords. Our effort in addressing this limitation
included cross-referencing studies cited from published
LCS systematic reviews with our database, as well as
conducting several supplemental searches to include
additional key search terms. Furthermore, it is important
to note again that evidence maps do not include quality
(risk of bias) appraisal of the included studies. Thus,
there can be a high volume of poor quality research and
more research is still needed despite this high volume.
There is a growing interest in engaging stakeholders in
evidence synthesis processes for the potential benefits of
improving relevant, enhancing quality, and increasing
Fig. 5 Role of evidence mapping in knowledge synthesis and translation*. *Modified from Elliott et al. Living systematic reviews: an emerging
opportunity to narrow the evidence-practice gap. PLoS Med. 2014 Feb 18;11(2):e1001603
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dissemination and uptake of evidence-based findings [21].
In this project, the iterative nature for defining outcomes
of interest with input from the stakeholders inevitably cre-
ated some subjectivity and uncertainties in the compre-
hensiveness of the search strategies because not all search
terms were pre-defined according to the standards for
conducting a systematic review. However, we could also
argue that the stakeholders’ input helped strengthen a
claim of comprehensiveness in capturing all important re-
search areas of interest. Initially 12,830 citations were
identified for further review, while using additional terms
from the stakeholder panel, another 4400 citations were
identified. This represents 34 % additional citations. Thus,
the iterative and collaborative nature of the process is not
a limitation, but rather strength for providing new dimen-
sions to the subject. Future work should identify concrete
criteria for evaluating the effectiveness of different
methods, timing, and intensity of stakeholder engagement.
Conclusion
Evidence mapping is a replicable evidence-based approach
to identify, collect and evaluate the characteristics of pub-
lished studies. The methodology is systematic and requires
less time and effort than a systematic review to achieve an
understanding and distribution of evidence. Evidence
mapping can also be used to identify both research gaps,
as well as areas of opportunity for systematic reviews. An
open evidence-map database has the potential to promote
knowledge translation from nutrition science to policy. To
achieve this ultimate goal, continuous updating, data qual-
ity control and validation would be required.
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